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Objective: Hematopoietic stem cell transplantation has been successfully used to treat the
pediatric population with malignant and non-malignant hematological diseases. This paper
reports the results up to 180 days after the procedure of all unrelated hematopoietic stem
cell transplantations in pediatric patients that were performed in one institution.
Methods: A retrospective review was performed of all under 18-year-old patients who
received unrelated transplantations between 1995 and 2009. Data were analyzed using the
log-rank test, Cox stepwise model, Kaplan–Meier method, Fine and Gray model and Fisher’s
exact  test.
Results: This study included 118 patients (46.8%) who received bone marrow and 134 (53.2%)
who received umbilical cord blood transplants. Engraftment occurred in 89.47% of the
patients that received bone marrow and 65.83% of those that received umbilical cord blood
(p-value < 0.001). Both neutrophil and platelet engraftments were faster in the bone marrow
group. Acute graft-versus-host disease occurred in 48.6% of the patients without statistically
signiﬁcant differences between the two groups (p-value = 0.653). Chronic graft-versus-host
disease occurred in 9.2% of the patients with a higher incidence in the bone marrow group
(p-value = 0.007). Relapse occurred in 24% of the 96 patients with malignant disease with 2-
year cumulative incidences of 45% in the bone marrow group and 25% in the umbilical cord
blood group (p-value = 0.117). Five-year overall survival was 47%, with an average survival
time  of 1207 days, and no signiﬁcant differences between the groups (p-value = 0.4666).
Conclusion: Despite delayed engraftment in the umbilical cord blood group, graft-versus-host
disease, relapse and survival were similar in both groups.©  2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.∗ Corresponding author at: Rua General Carneiro, 181, Alto da Glória, 80
E-mail address: dhmarinho@hotmail.com (D.H. Marinho).
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Table 1 – Features of patients and treatment.
Variable
Age – mean (range) years 8 (0.2–18.0)
Diagnoses – n (%)
Malignant disease 96 (38.1)
Marrow failure 95 (37.7)
Immune deﬁciency 42 (16.7)
Metabolic disorders 19 (7.5)
Source of stem cell – n (%)
Bone marrow 118 (46.8)
Umbilical cord blood 134 (53.2)
Degree of HLA match – n (%)
Without incompatibility (BM) 71 (60.2)
One/more incompatibility (BM) 47 (39.8)
Without or one incompatibility (UCB) 76 (56.7)
Two/more incompatibility (UCB) 58 (43.3)
Conditioning regimen – n (%)
CFA + FLU 106 (42.4)
CFA + TBI 47 (18.8)
CFA + BU 58 (23.2)
CFA + BU + MEL 8 (3.2)
Others 31 (12.4)
ATG 174 (69.0)
GVHD prophylaxis – n (%)
CsA + MTX 144 (57.1)
CsA + steroids 91 (36.1)
Others 17 (6.7)
CFA: cyclophosphamide; FLU: ﬂudarabine; TBI: total body irradia-
tion; BU: busulfan; MEL: melphalan; ATG: anti-thymocyte globulin;rev bras hematol hemot
ntroduction
llogeneic hematopoietic stem cell transplantation (HSCT) is
n accepted treatment for a number of inherited and acquired
ematopoietic diseases in children, especially diseases for
hich an alternative treatment is not available or no longer
ffective.1,2
Human leukocyte antigen (HLA)-matched sibling donors
re available only for around 25% of such children. However,
here has been substantial progress over the last four decades
n the use of alternative donors, including unrelated volunteer
onors.3–5
The known advantages of unrelated umbilical cord blood
UCB) over unrelated bone marrow (BM) are well docu-
ented and include: signiﬁcantly faster availability of banked
ryopreserved UCB units, no risk to the donor, reduced trans-
ission of viral illnesses such as cytomegalovirus (CMV) and
pstein Barr virus (EBV), tolerance of HLA disparity between
he donor and recipient, and reduced risk and severity of
cute graft-versus-host disease (GVHD). However, the main
roblem of using UCB for transplantation is the low number
f hematopoietic progenitor cells, which results in increased
isk of graft failure, delayed hematopoietic engraftment and
elayed immune reconstitution.6,7
HLA matching, the use of high-dose chemotherapy and/or
adiotherapy and the need of immunosuppressive drugs rep-
esent the causes of onset of many  complications following
SCT.8,9
GVHD is a common complication, mainly in unrelated
SCT or in the presence of any HLA allele mismatch.10 At an
ncidence of 40%, acute GVHD occurs in the early period after
ransplant with the skin being the most commonly affected
issue. Risk factors for the development of GVHD include the
ecipient’s age, CMV  serostatus, HSC donor source and HLA
isparity.11,12 Chronic GVHD is observed in 30–90% of recipi-
nts of HSCT.3
In patients with malignant diseases, GVHD is associated
ith the graft-versus-leukemia effect (GVL), thus resulting in
 decreased incidence of relapse.13,14
In recent decades, the overall survival (OS) in children who
eceived HSCT is much higher, about 60% one to two years
fter transplant, depending on the disease, clinical conditions
rior to transplant and complications after the transplant.2,6
herefore, this study aimed to analyze the results of unrelated
SCT in pediatric patients up to 180 days after the procedure
nd to compare the stem cell sources used.
ethods
atients
his is a retrospective study. Between January 1995 and
ecember 2009, 261 under 18-year-old patients received unre-
ated HSCT at the Hospital de Clínicas, Universidade Federal do
araná (UFPR), Brazil. Of the 261 patients, nine were excluded
rom the analysis for the following reasons: seven patients had
nsufﬁcient data for analysis and two patients were recipients
f peripheral blood transplants. One hundred and eighteenCsA: cyclosporine; MTX: methotrexate.
patients received BM and 134 UCB grafts. The characteristics
of the 252 cases that were assessed are listed in Table 1.
HLA  typing  and  unrelated  donor  selection
The units were selected on the basis of best HLA matching and
a critical minimum cell dose at the discretion of the treating
physicians and source from National and International Public
Banks. Class I typing was performed by serological or molecu-
lar techniques and Class II typing by molecular techniques; it
was only in 2008 that the analysis of the locus C was frequently
performed.
Conditioning  regimen  and  prophylaxis  against
graft-versus-host  disease
The conditioning regimen and prophylaxis for acute GVHD
varied according to the underlying disease, stem cell source
and HLA incompatibilities (Table 1).
Transplantation
The units of BM grafts used for transplantation contained
an average of 4.39 × 108 total nucleated cells (TNC) (range:
0.3–10.8 cells) per kilogram of recipient’s body weight after
thawing. The units of UCB grafts used for transplantation con-
tained an average of 5.2 × 107 TNC (range: 1.4–36.5 cells) and
oter.
(p-value < 0.001) and HLA match (p-value = 0.013) were signiﬁ-
cantly favorable factors for platelet engraftment (Table 2 and
Figure 2).
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1.3 × 105 CD34 cells (range: 0.1–11.4 cells) per kilogram of recip-
ient’s body weight after thawing.
Supportive  care
Central venous catheters were inserted in all patients.
Patients received acyclovir for antiviral prophylaxis, ﬂu-
conazole or amphotericin-B for antifungal prophylaxis, and
trimethoprim-sulfamethoxazole for prophylaxis against Pneu-
mocystis carinii.  Empirical broad spectrum antibiotic therapy
was started at the ﬁrst sign of fever.
Hematopoietic  recovery  and  engraftment
Hematologic recovery was deﬁned as the time when the
absolute neutrophil count was equal to or greater than
0.5 × 109 cells/L in three consecutive laboratory counts on
different days and platelet count equal to or greater
than 20 × 109 cells/L (after seven days without transfusion
support).6
Graft-versus-host  disease
Patients were evaluated and considered at risk for acute
GVHD when there was evidence of neutrophil recovery. Diag-
nosis of acute GVHD was based on clinical criteria, with
histopathologic conﬁrmation when possible. Overall staging
was assessed according to previously published criteria.15
Only those patients with sustained engraftment of donor
hematopoiesis surviving for more  than 90 days after trans-
plant were assessed for chronic GVHD according to the criteria
described in previous studies.16
Other  measurements
Relapse was characterized by morphological evidence of
malignant disease at any site. Transplant-related mortality
(TRM) was determined to be every cause of death that was
not death by relapse. OS was the time between transplanta-
tion and death due to any cause or between transplantation
and the day of the last follow-up.
Statistical  analysis
All statistical analyses were carried out using the STATA v.12.0
computer program. Survival rates were calculated using the
Kaplan–Meier method. The log-rank test was used for test-
ing differences in survival between groups in the univariate
analysis. Cumulative incidence curves were used for engraft-
ment and GVHD endpoints with death as a competing risk
factor. The Cox proportional hazards model with backward
elimination was used for multivariate testing of co-variables
(statistical signiﬁcance was based on p-values ≤ 0.05). Differ-
ences between subgroups were compared using the Fine and
Gray test with death as a competing risk. The association
between dichotomous variables was calculated using Fisher’s
exact test. 2 0 1 5;3  7(4):236–241
Results
Patient  characteristics
From 1995 to 2009, 252 patients were treated with unrelated
HSCT. The mean age of the patients was eight years (range:
0.2–18 years) with 34 patients being one year old or less.
Most patients were male (61.1%). A total of 96 patients were
transplanted for malignant diseases with 64 (66.7%) being at
an early stage. A total of 150 (59.5%) donor-graft pairs were
matched for ABO and 124 (49.8%) were matched for gender.
BM was used for HSCT in 118 patients (46.8%) and UCB in 134
patients (53.2%). The patients as well as treatment are listed
in Table 1.
Neutrophil  and  platelet  engraftment
Neutrophil engraftment occurred in 181 of the 234 (77.4%)
avaliable (18 patients died before) cases (BM: 89.47% and UCB:
65.83%). In the BM group, 102 of the 118 patients achieved
neutrophil engraftment in an average time of 24 days (range:
11–1696 days). The cumulative incidence by Day 30 was 80%.
In the UCB group, 79 of the 134 patients achieved neutrophil
engraftment in a mean time of 32 days (range: 14–4037 days).
The cumulative incidence by Day 42 was 62%. In the uni-
variate analysis, neutrophil engraftment was inﬂuenced by
cell source (p-value < 0.001) and patient age (p-value = 0.002).
In the multivariate analysis only cell source (p-value < 0.001)
was a signiﬁcantly favorable factor for neutrophil engraftment
(Table 2 and Figure 1).
In the BM group, patients achieved platelet engraftment in
an average of 25 days (range: 10–96 days). The cumulative inci-
dence by Day 30 was 50%. In the UCB group, patients achieved
platelet engraftment in a mean time of 43 days (range: 19–158
days). The cumulative incidence by Day 42 was 38%. In the uni-
variate analysis, platelet engraftment was inﬂuenced by cell
source (p-value < 0.001), patient age (p-value = 0.022) and HLA
match (p-value = 0.027). In the multivariate analysis cell source0
0 30 60 90 120 150 160
Days
Figure 1 – Cumulative incidence of neutrophil engraftment
over time.
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Table 2 – Multivariate analysis.
Variable Hazard ratio 95% Conﬁdence interval p-Value Favorable factor
Neutrophil engraftment
Stem cell source 0.37 0.25–0.54 <0.001 Bone marrow
Age 0.99 0.96–1.03 0.744
Platelet engraftment
Stem cell source 0.36 0.24–0.54 <0.001 Bone marrow
Age 0.52 0.94–1.03 0.520
HLA 0.63 0.43–0.90 0.013 Without mismatch
Acute GVHD
HLA 1.74 1.20–2.52 0.003 Without mismatch
ATG 0.58 0.40–0.86 0.006 Use
Relapse
Disease status 3.27 1.44–7.42 0.005 CR1/2
Overall survival
Age (years) 1.11 1.04–1.18 <0.001 Young
GVHD 2.55 1.29–5.04 0.007 Without
ATG 1.99 1.07–3.72 0.029 Use
HLA: human leukocyte antigen; GVHD: graft-versus-host disease; ATG: anti-thymocyte globulin; CR1/2: complete remission 1/2.
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Figure 2 – Cumulative incidence of platelet engraftment
over time.
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Figure 3 – Cumulative incidence of acute graft-versus-hostraft-versus-host  disease
cute GVHD occurred in 88 (48.6%) patients of the total of
81 (on average within 90 days) and was scored as Grade II
54.5%) and Grade III–IV (45.5%). By Day 100 after transplanta-
ion, the cumulative incidence was 44% in the BM group and
3% in the UCB group (p-value = 0.653 – Figure 3). HLA match
p-value = 0.004) and ATG (p-value = 0.005) were signiﬁcant in
he univariate analysis; this was the same in the multivari-
te analysis (p-value = 0.003 and p-value = 0.006, respectively –
able 2).
Chronic GVHD occurred in 13 (9.2%) patients out of the total
f 142 (on average within 90 days). The disease was classiﬁed
s limited in six cases (46.2%) and extensive in seven cases
53.8%). At one year after transplantation, the cumulative inci-
ence was 14% in the BM group and 2.5% in the UCB group
p-value = 0.053).disease over time.
Relapse
Hematological relapse was detected between 21 and 1228 days
(mean: 181 days; 95% conﬁdence interval: 94.0–670.0) after
transplantation in 23 of 96 patients treated for malignant dis-
ease. Relapse was observed in 29.31% of the patients in the
BM group and 15.79% in the UCB group (p-value = 0.117). The
cumulative incidences of relapse were 45% in the BM group
and 25% in the UCB group at two years (Figure 4). The stage of
the disease was found to be signiﬁcant (p-value = 0.005) how-
ever cell source, GVHD, CMV and ABO incompatibility were not
(Table 2).
Overall  survival  and  causes  of  deathWith an average follow-up time of surviving patients of 1207
days (3.3 years), the cumulative proportions of surviving
patients at one year and ﬁve years were 55% and 47%, respec-
tively. The cumulative proportions of surviving patients at one
240  rev bras hematol hemoter.
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year and ﬁve years after unrelated HSCT with BM were 55% and
45%, respectively and for UCB they were 52% and 45%, respec-
tively (p-value = 0.466) (Figure 5). In a multivariate analysis, the
factors that most inﬂuenced of negative form the OS were
higher ages (p-value < 0.001), non-use of ATG (p-value = 0.029),
and GVHD (p-value = 0.007 – Table 2).
In this series, 131 (52.0%) patients died, 59 (50.0%) in the BM
group and 72 (53.73%) in the UCB group (p-value = 0.614). Death
was associated with infection (n = 47), graft failure (n = 29),
GVHD (n = 25), relapse (n = 18) and others (n = 12).
Discussion
This retrospective study compared a heterogeneous pediatric
population with different diagnoses transplanted over a long
period of time using two different stem cell sources. This
study aimed to evaluate the outcomes of unrelated HSCT in
the pediatric population comparing the use of BM and UCB;
only 25% of patients who  need transplants ﬁnd suitable family
donors.The cumulative incidence (80% by Day 30 in the BM group,
and 62% by Day 42 in the UCB group) and speed of neutrophil
engraftment (on average by Day 24 in the BM group and Day
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Figure 5 – Cumulative incidence of overall survival over
time. 2 0 1 5;3  7(4):236–241
32 in the UCB group) were similar to the results of Barker
et al.17 In other studies on UCB transplantations6,18,19 neu-
trophil engraftment was found higher and faster than in the
current study. In this study, neutrophil engraftment was not
inﬂuenced by HLA matching similar to the study of Petterson
et al.6 even though Kurtzberg et al.18 found that HLA matching
inﬂuenced neutrophil engraftment. It is known that, during
the time of this study, HLA typing techniques were improved.
Many studies1,6,19 demonstrated that the dose of infused CD34
cells inﬂuences neutrophil engraftment, however no differ-
ence was seen in the current study perhaps due to the low
mean cell count infused.
The cumulative incidence (50% by Day 30 in the BM group,
and 38% by Day 42 in the UCB group) and speed (on aver-
age, Day 25 in the BM group and Day 43 in the UCB group) of
platelet engraftment were similar to Barker et al.12 Petterson
et al.,6 who analyzed patients who received UCB transplanta-
tion, found that platelet engraftment was similar to this study.
The authors reported that engraftment was not inﬂuenced by
the infused TNC or CD34 cell dose or HLA matching. However
in the current study, platelet engraftment was inﬂuenced by
HLA matching. It is again important to note that HLA typing
techniques were improved during this period.
Acute GVHD remains a major cause of morbidity and
mortality after HSCT. The incidence of Grade II–IV GVHD
is between 20 and 50%. The recipient’s age, CMV serosta-
tus, donor source and HLA disparity have consistently been
found to be risk factors for the development of acute GVHD.12
This study demonstrates that 48.6% of the patients devel-
oped acute GVHD with Grade II being found in 54.5% of the
cases. Some studies12,18,19 demonstrated similar incidences,
however others2,10 found lower incidences, and Faraci et al.20
found an incidence of 75%. In this report, as well in Barker
et al.17 and Hwang et al.,21 there was no difference in the inci-
dence of acute GVHD between the BM and the UCB  groups;
however, Wang et al.22 reported that the incidence was lower
in the UCB group.
The incidence of chronic GVHD ranges between 30% and
50% and thus is a major cause of non-relapse mortality and
morbidity in long-term survivors. Chronic GVHD is associ-
ated with a graft-versus-leukemia effect (GVL) resulting in a
decreased incidence of relapse.13 In this study, the incidence
was 9.2% versus 25.0% as reported by Zecca et al.13 However in
this study the follow-up was only up to 180 days after trans-
plant. Similar to other reports,21,22 chronic GVHD occurred
more  in the BM group (p-value = 0.007). Barker et al.17 reported
no difference between the two groups.
Relapse occurred in 24% of the patients who received HSCT
for malignant diseases with the incidence being similar in
both groups. Wang et al.22 stated that relapse was lower in
the UCB group. GVHD did not show a GVL effect, similar to the
report by Lee et al.23; however Yi et al.24 believe that GVHD
has an important protective role. The stage of the disease was
important for prognosis in this study and in others.18,25
The estimated one-year OS after HSCT in the BM and the
UCB groups were 58% and 52%, respectively (p-value = 0.466).
These data were found to be similar to the literature.3,6,17 In
the multivariate analysis, the results associated with a sig-
niﬁcantly worse OS included higher age, non-use of ATG and
GVHD. Petterson et al.6 reported that only patients with GVHD
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ad worse survival, and Wagner et al.1 stated that HLA mis-
atch inﬂuenced survival too. Infection was the main cause
f death as in other publications.2,25
onclusion
ur ﬁndings conﬁrm that unrelated HSCT with BM and UCB
esults in similar complications and survival in the pediatric
opulation. Therefore, UCB is a safe cell source for patients
ho  do not have a sibling donor for HSCT.
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